How far should surgeons go? study tests lymph node removal in uterine cancer
NCT ID NCT07306195
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 150 women with intermediate- or high-risk endometrial cancer who had surgery to remove the uterus and nearby lymph nodes. Researchers compared removing lymph nodes up to a higher level (near the kidney) versus a lower level (near the pelvis) to see which approach removed more nodes and improved cancer staging. The goal is to find the best surgical method to guide further treatment and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- surgical procedure (para-aortic lymphadenectomy)
- What this could lead to
- If successful, this could help determine the best extent of lymph node removal to improve staging and survival in endometrial cancer.
- What could go wrong
- This is a completed study with 150 participants, but results may not apply to all patients. Higher-level dissection may increase surgical risks without clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
150 people
The number who actually took part.
- Started
-
Oct 2022
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The inclusion criteria consisted of women diagnosed with either intermediate- or high-risk EC, based on established pathological and radiological criteria. •Intermediate-risk patients included those with grade 1/2 endometrioid carcinoma with \<50% myometrial invasion and tumor size \>2 cm, grade 1/2 with 50-66% invasion, or grade 3 with \<50% invasion. * High-risk cases were defined as non-endometrioid histology (serous or clear cell), grade 1 or 2 endometrioid carcinoma with more than 66% invasion, grade 3 with more than 50% invasion, or the presence of adnexal metastasis. Exclusion Criteria: * Patients were excluded if they had general contraindications to surgery, morbid obesity that precluded safe operative access, or if they declined to participate.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kafr Elsheikh University Hospital
Kafr ash Shaykh, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can hormone pills replace chemo for aggressive endometrial cancer?
- Triple oral drug combo targets two stubborn gynecologic cancers
- Shorter, personalized radiation may target endometrial cancer with fewer side effects
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a Weight-Loss drug and an IUD treat early uterine cancer without surgery?
- Blood test aims to catch Cancer's return earlier